[Pharmacokinetics of gadolinium-based contrast agents].

CONCLUSIONS: Risks and benefits should be considered on an individual basis before MRI with gadolinium-based contrast agents (expected benefit, potentially undetected risks, available alternatives and their risks). Quantification of gadolinium in urine or blood from patients is not meaningful and should not be done outside clinical studies. PMID: 30725143 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30725143?dopt=Abstract

Source: Der Radiologe - February 6, 2019 Category: Radiology Authors: Czock D Tags: Radiologe Source Type: research